EP4667588A2 — Methods of prognosis and treating cancer patients
Assigned to Novartis AG · Expires 2025-12-24 · 0y expired
What this patent protects
The disclosure is directed to novel predictive methods and personalized therapies for treating a patient with cancer such as breast cancer. Specifically, this disclosure relates to methods of treating a patient having cancer by selectively administering a combination of CDK 4/6 i…
USPTO Abstract
The disclosure is directed to novel predictive methods and personalized therapies for treating a patient with cancer such as breast cancer. Specifically, this disclosure relates to methods of treating a patient having cancer by selectively administering a combination of CDK 4/6 inhibitor and letrozole. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having cancer, e.g., breast cancer will respond to treatment with a combination of a CDK 4/6 inhibitor, e.g., a ribociclib and an aromatase inhibitor, letrozol.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.